Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $49000.0.

  • Foghorn Therapeutics' Cash from Financing Activities fell 9533.78% to $49000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $446000.0, marking a year-over-year decrease of 9957.77%. This contributed to the annual value of $105.4 million for FY2024, which is 582958.38% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Cash from Financing Activities stood at $49000.0 for Q3 2025, which was down 9533.78% from $254000.0 recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Cash from Financing Activities registered a high of $103.2 million during Q2 2024, and its lowest value of $4000.0 during Q4 2024.
  • Its 5-year average for Cash from Financing Activities is $6.9 million, with a median of $254000.0 in 2025.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 9992.64% in 2022, then surged by 10010000.0% in 2024.
  • Foghorn Therapeutics' Cash from Financing Activities (Quarter) stood at $21.7 million in 2021, then tumbled by 99.93% to $16000.0 in 2022, then surged by 1062.5% to $186000.0 in 2023, then plummeted by 97.85% to $4000.0 in 2024, then surged by 1125.0% to $49000.0 in 2025.
  • Its Cash from Financing Activities was $49000.0 in Q3 2025, compared to $254000.0 in Q2 2025 and $139000.0 in Q1 2025.